APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis A immunoglobulin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hepatitis A immunoglobulin Market Outlook and Growth Opportunities 2026

Report ID 173997870430 December 2025197 pages

Choose your research edition.

Industry ResearchHepatitis A immunoglobulin Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis A immunoglobulin Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Hepatitis A immunoglobulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis A immunoglobulin Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis A immunoglobulin Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Hepatitis A immunoglobulin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hepatitis A immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatitis A immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatitis A immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hepatitis A immunoglobulin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hepatitis A immunoglobulin market include CSL Behring, Dr. Reddy's Laboratories, Native Antigen, AIM Vaccine, GSK, Sinovac Biotech, Merck, Pukang Biotechnology and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hepatitis A immunoglobulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatitis A immunoglobulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatitis A immunoglobulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis A immunoglobulin market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatitis A immunoglobulin Segment by Company

CSL Behring

Dr. Reddy's Laboratories

Native Antigen

AIM Vaccine

GSK

Sinovac Biotech

Merck

Pukang Biotechnology

Sanofi

Changchun Lnstitute Of Biological Products

Zhifei Biological Products

Hepatitis A immunoglobulin Segment by Type

Inactivated

Attenuated

Hepatitis A immunoglobulin Segment by Application

Hospital

Pharmacy

Other

Hepatitis A immunoglobulin Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Hepatitis A immunoglobulin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hepatitis A immunoglobulin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatitis A immunoglobulin significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatitis A immunoglobulin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis A immunoglobulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis A immunoglobulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis A immunoglobulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatitis A immunoglobulin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatitis A immunoglobulin industry.

Chapter 3: Detailed analysis of Hepatitis A immunoglobulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hepatitis A immunoglobulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hepatitis A immunoglobulin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatitis A immunoglobulin Industry Trends Table 2. Hepatitis A immunoglobulin Industry Drivers Table 3. Hepatitis A immunoglobulin Industry Opportunities and Challenges Table 4. Hepatitis A immunoglobulin Industry Restraints Table 5. Global Hepatitis A immunoglobulin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatitis A immunoglobulin Revenue Share by Company (2021-2026) Table 7. Global Hepatitis A immunoglobulin Sales Volume by Company (Units) & (2021-2026) Table 8. Global Hepatitis A immunoglobulin Sales Volume Share by Company (2021-2026) Table 9. Global Hepatitis A immunoglobulin Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Hepatitis A immunoglobulin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hepatitis A immunoglobulin Key Company Manufacturing Base & Headquarters Table 12. Global Hepatitis A immunoglobulin Company, Product Type & Application Table 13. Global Hepatitis A immunoglobulin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatitis A immunoglobulin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Inactivated Table 18. Significant Companies of Attenuated Table 19. Global Hepatitis A immunoglobulin Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 20. Global Hepatitis A immunoglobulin Sales Volume by Type (2021-2026) & (Units) Table 21. Global Hepatitis A immunoglobulin Sales Volume by Type (2027-2032) & (Units) Table 22. Global Hepatitis A immunoglobulin Sales Volume Share by Type (2021-2026) Table 23. Global Hepatitis A immunoglobulin Sales Volume Share by Type (2027-2032) Table 24. Global Hepatitis A immunoglobulin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hepatitis A immunoglobulin Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hepatitis A immunoglobulin Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hepatitis A immunoglobulin Sales Value Share by Type (2021-2026) Table 28. Global Hepatitis A immunoglobulin Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Hepatitis A immunoglobulin Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 33. Global Hepatitis A immunoglobulin Sales Volume by Application (2021-2026) & (Units) Table 34. Global Hepatitis A immunoglobulin Sales Volume by Application (2027-2032) & (Units) Table 35. Global Hepatitis A immunoglobulin Sales Volume Share by Application (2021-2026) Table 36. Global Hepatitis A immunoglobulin Sales Volume Share by Application (2027-2032) Table 37. Global Hepatitis A immunoglobulin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hepatitis A immunoglobulin Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Hepatitis A immunoglobulin Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Hepatitis A immunoglobulin Sales Value Share by Application (2021-2026) Table 41. Global Hepatitis A immunoglobulin Sales Value Share by Application (2027-2032) Table 42. Global Hepatitis A immunoglobulin Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 43. Global Hepatitis A immunoglobulin Sales by Region (2021-2026) & (Units) Table 44. Global Hepatitis A immunoglobulin Sales Market Share by Region (2021-2026) Table 45. Global Hepatitis A immunoglobulin Sales by Region (2027-2032) & (Units) Table 46. Global Hepatitis A immunoglobulin Sales Market Share by Region (2027-2032) Table 47. Global Hepatitis A immunoglobulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Hepatitis A immunoglobulin Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Hepatitis A immunoglobulin Sales Value Share by Region (2021-2026) Table 50. Global Hepatitis A immunoglobulin Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Hepatitis A immunoglobulin Sales Value Share by Region (2027-2032) Table 52. Global Hepatitis A immunoglobulin Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Hepatitis A immunoglobulin Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Hepatitis A immunoglobulin Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 55. Global Hepatitis A immunoglobulin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Hepatitis A immunoglobulin Sales by Country (2021-2026) & (Units) Table 57. Global Hepatitis A immunoglobulin Sales Market Share by Country (2021-2026) Table 58. Global Hepatitis A immunoglobulin Sales by Country (2027-2032) & (Units) Table 59. Global Hepatitis A immunoglobulin Sales Market Share by Country (2027-2032) Table 60. Global Hepatitis A immunoglobulin Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Hepatitis A immunoglobulin Sales Value Market Share by Country (2021-2026) Table 62. Global Hepatitis A immunoglobulin Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Hepatitis A immunoglobulin Sales Value Market Share by Country (2027-2032) Table 64. CSL Behring Company Information Table 65. CSL Behring Business Overview Table 66. CSL Behring Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. CSL Behring Hepatitis A immunoglobulin Product Portfolio Table 68. CSL Behring Recent Development Table 69. Dr. Reddy's Laboratories Company Information Table 70. Dr. Reddy's Laboratories Business Overview Table 71. Dr. Reddy's Laboratories Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Dr. Reddy's Laboratories Hepatitis A immunoglobulin Product Portfolio Table 73. Dr. Reddy's Laboratories Recent Development Table 74. Native Antigen Company Information Table 75. Native Antigen Business Overview Table 76. Native Antigen Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Native Antigen Hepatitis A immunoglobulin Product Portfolio Table 78. Native Antigen Recent Development Table 79. AIM Vaccine Company Information Table 80. AIM Vaccine Business Overview Table 81. AIM Vaccine Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. AIM Vaccine Hepatitis A immunoglobulin Product Portfolio Table 83. AIM Vaccine Recent Development Table 84. GSK Company Information Table 85. GSK Business Overview Table 86. GSK Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. GSK Hepatitis A immunoglobulin Product Portfolio Table 88. GSK Recent Development Table 89. Sinovac Biotech Company Information Table 90. Sinovac Biotech Business Overview Table 91. Sinovac Biotech Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Sinovac Biotech Hepatitis A immunoglobulin Product Portfolio Table 93. Sinovac Biotech Recent Development Table 94. Merck Company Information Table 95. Merck Business Overview Table 96. Merck Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Merck Hepatitis A immunoglobulin Product Portfolio Table 98. Merck Recent Development Table 99. Pukang Biotechnology Company Information Table 100. Pukang Biotechnology Business Overview Table 101. Pukang Biotechnology Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Pukang Biotechnology Hepatitis A immunoglobulin Product Portfolio Table 103. Pukang Biotechnology Recent Development Table 104. Sanofi Company Information Table 105. Sanofi Business Overview Table 106. Sanofi Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Sanofi Hepatitis A immunoglobulin Product Portfolio Table 108. Sanofi Recent Development Table 109. Changchun Lnstitute Of Biological Products Company Information Table 110. Changchun Lnstitute Of Biological Products Business Overview Table 111. Changchun Lnstitute Of Biological Products Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Changchun Lnstitute Of Biological Products Hepatitis A immunoglobulin Product Portfolio Table 113. Changchun Lnstitute Of Biological Products Recent Development Table 114. Zhifei Biological Products Company Information Table 115. Zhifei Biological Products Business Overview Table 116. Zhifei Biological Products Hepatitis A immunoglobulin Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Zhifei Biological Products Hepatitis A immunoglobulin Product Portfolio Table 118. Zhifei Biological Products Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Hepatitis A immunoglobulin Distributors List Table 122. Hepatitis A immunoglobulin Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Hepatitis A immunoglobulin Product Image Figure 2. Global Hepatitis A immunoglobulin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis A immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hepatitis A immunoglobulin Sales (2021-2032) & (Units) Figure 5. Global Hepatitis A immunoglobulin Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Hepatitis A immunoglobulin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Inactivated Image Figure 10. Attenuated Image Figure 11. Global Hepatitis A immunoglobulin Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 12. Global Hepatitis A immunoglobulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hepatitis A immunoglobulin Sales Volume Share by Type (2021-2032) Figure 14. Global Hepatitis A immunoglobulin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hepatitis A immunoglobulin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hepatitis A immunoglobulin Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Hepatitis A immunoglobulin Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 21. Global Hepatitis A immunoglobulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Hepatitis A immunoglobulin Sales Volume Share by Application (2021-2032) Figure 23. Global Hepatitis A immunoglobulin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Hepatitis A immunoglobulin Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Hepatitis A immunoglobulin Sales Value Share by Application (2021-2032) Figure 26. Global Hepatitis A immunoglobulin Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 27. Global Hepatitis A immunoglobulin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Hepatitis A immunoglobulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Hepatitis A immunoglobulin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Hepatitis A immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 31. North America Hepatitis A immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Hepatitis A immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Hepatitis A immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Hepatitis A immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Hepatitis A immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Hepatitis A immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 37. South America Hepatitis A immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Hepatitis A immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Hepatitis A immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Hepatitis A immunoglobulin Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Hepatitis A immunoglobulin Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Inactivated
  • Attenuated
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • CSL Behring
  • Dr. Reddy's Laboratories
  • Native Antigen
  • AIM Vaccine
  • GSK
  • Sinovac Biotech
  • Merck
  • Pukang Biotechnology
  • Sanofi
  • Changchun Lnstitute Of Biological Products
  • Zhifei Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatitis A immunoglobulin Sales Value (2021-2032)
  4. 1.2.2 Global Hepatitis A immunoglobulin Sales Volume (2021-2032)
  5. 1.2.3 Global Hepatitis A immunoglobulin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hepatitis A immunoglobulin Market Dynamics
  1. 2.1 Hepatitis A immunoglobulin Industry Trends
  2. 2.2 Hepatitis A immunoglobulin Industry Drivers
  3. 2.3 Hepatitis A immunoglobulin Industry Opportunities and Challenges
  4. 2.4 Hepatitis A immunoglobulin Industry Restraints
3 Hepatitis A immunoglobulin Market by Company
  1. 3.1 Global Hepatitis A immunoglobulin Company Revenue Ranking in 2025
  2. 3.2 Global Hepatitis A immunoglobulin Revenue by Company (2021-2026)
  3. 3.3 Global Hepatitis A immunoglobulin Sales Volume by Company (2021-2026)
  4. 3.4 Global Hepatitis A immunoglobulin Average Price by Company (2021-2026)
  5. 3.5 Global Hepatitis A immunoglobulin Company Ranking (2024-2026)
  6. 3.6 Global Hepatitis A immunoglobulin Company Manufacturing Base and Headquarters
  7. 3.7 Global Hepatitis A immunoglobulin Company Product Type and Application
  8. 3.8 Global Hepatitis A immunoglobulin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hepatitis A immunoglobulin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hepatitis A immunoglobulin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hepatitis A immunoglobulin Market by Type
  1. 4.1 Hepatitis A immunoglobulin Type Introduction
  2. 4.1.1 Inactivated
  3. 4.1.2 Attenuated
  4. 4.2 Global Hepatitis A immunoglobulin Sales Volume by Type
  5. 4.2.1 Global Hepatitis A immunoglobulin Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hepatitis A immunoglobulin Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hepatitis A immunoglobulin Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hepatitis A immunoglobulin Sales Value by Type
  9. 4.3.1 Global Hepatitis A immunoglobulin Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hepatitis A immunoglobulin Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hepatitis A immunoglobulin Sales Value Share by Type (2021-2032)
5 Hepatitis A immunoglobulin Market by Application
  1. 5.1 Hepatitis A immunoglobulin Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Hepatitis A immunoglobulin Sales Volume by Application
  6. 5.2.1 Global Hepatitis A immunoglobulin Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatitis A immunoglobulin Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hepatitis A immunoglobulin Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hepatitis A immunoglobulin Sales Value by Application
  10. 5.3.1 Global Hepatitis A immunoglobulin Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hepatitis A immunoglobulin Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hepatitis A immunoglobulin Sales Value Share by Application (2021-2032)
6 Hepatitis A immunoglobulin Regional Sales and Value Analysis
  1. 6.1 Global Hepatitis A immunoglobulin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatitis A immunoglobulin Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatitis A immunoglobulin Sales by Region: 2021-2026
  4. 6.2.2 Global Hepatitis A immunoglobulin Sales by Region (2027-2032)
  5. 6.3 Global Hepatitis A immunoglobulin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hepatitis A immunoglobulin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hepatitis A immunoglobulin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hepatitis A immunoglobulin Sales Value by Region (2027-2032)
  9. 6.5 Global Hepatitis A immunoglobulin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hepatitis A immunoglobulin Sales Value (2021-2032)
  12. 6.6.2 North America Hepatitis A immunoglobulin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hepatitis A immunoglobulin Sales Value (2021-2032)
  15. 6.7.2 Europe Hepatitis A immunoglobulin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hepatitis A immunoglobulin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hepatitis A immunoglobulin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hepatitis A immunoglobulin Sales Value (2021-2032)
  21. 6.9.2 South America Hepatitis A immunoglobulin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hepatitis A immunoglobulin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hepatitis A immunoglobulin Sales Value Share by Country, 2025 VS 2032
7 Hepatitis A immunoglobulin Country-level Sales and Value Analysis
  1. 7.1 Global Hepatitis A immunoglobulin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatitis A immunoglobulin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hepatitis A immunoglobulin Sales by Country (2021-2032)
  4. 7.3.1 Global Hepatitis A immunoglobulin Sales by Country (2021-2026)
  5. 7.3.2 Global Hepatitis A immunoglobulin Sales by Country (2027-2032)
  6. 7.4 Global Hepatitis A immunoglobulin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hepatitis A immunoglobulin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hepatitis A immunoglobulin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hepatitis A immunoglobulin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hepatitis A immunoglobulin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hepatitis A immunoglobulin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL Behring
  2. 8.1.1 CSL Behring Company Information
  3. 8.1.2 CSL Behring Business Overview
  4. 8.1.3 CSL Behring Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSL Behring Hepatitis A immunoglobulin Product Portfolio
  6. 8.1.5 CSL Behring Recent Developments
  7. 8.2 Dr. Reddy's Laboratories
  8. 8.2.1 Dr. Reddy's Laboratories Company Information
  9. 8.2.2 Dr. Reddy's Laboratories Business Overview
  10. 8.2.3 Dr. Reddy's Laboratories Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Dr. Reddy's Laboratories Hepatitis A immunoglobulin Product Portfolio
  12. 8.2.5 Dr. Reddy's Laboratories Recent Developments
  13. 8.3 Native Antigen
  14. 8.3.1 Native Antigen Company Information
  15. 8.3.2 Native Antigen Business Overview
  16. 8.3.3 Native Antigen Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Native Antigen Hepatitis A immunoglobulin Product Portfolio
  18. 8.3.5 Native Antigen Recent Developments
  19. 8.4 AIM Vaccine
  20. 8.4.1 AIM Vaccine Company Information
  21. 8.4.2 AIM Vaccine Business Overview
  22. 8.4.3 AIM Vaccine Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AIM Vaccine Hepatitis A immunoglobulin Product Portfolio
  24. 8.4.5 AIM Vaccine Recent Developments
  25. 8.5 GSK
  26. 8.5.1 GSK Company Information
  27. 8.5.2 GSK Business Overview
  28. 8.5.3 GSK Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GSK Hepatitis A immunoglobulin Product Portfolio
  30. 8.5.5 GSK Recent Developments
  31. 8.6 Sinovac Biotech
  32. 8.6.1 Sinovac Biotech Company Information
  33. 8.6.2 Sinovac Biotech Business Overview
  34. 8.6.3 Sinovac Biotech Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sinovac Biotech Hepatitis A immunoglobulin Product Portfolio
  36. 8.6.5 Sinovac Biotech Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck Hepatitis A immunoglobulin Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Pukang Biotechnology
  44. 8.8.1 Pukang Biotechnology Company Information
  45. 8.8.2 Pukang Biotechnology Business Overview
  46. 8.8.3 Pukang Biotechnology Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pukang Biotechnology Hepatitis A immunoglobulin Product Portfolio
  48. 8.8.5 Pukang Biotechnology Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Hepatitis A immunoglobulin Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
  55. 8.10 Changchun Lnstitute Of Biological Products
  56. 8.10.1 Changchun Lnstitute Of Biological Products Company Information
  57. 8.10.2 Changchun Lnstitute Of Biological Products Business Overview
  58. 8.10.3 Changchun Lnstitute Of Biological Products Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Changchun Lnstitute Of Biological Products Hepatitis A immunoglobulin Product Portfolio
  60. 8.10.5 Changchun Lnstitute Of Biological Products Recent Developments
  61. 8.11 Zhifei Biological Products
  62. 8.11.1 Zhifei Biological Products Company Information
  63. 8.11.2 Zhifei Biological Products Business Overview
  64. 8.11.3 Zhifei Biological Products Hepatitis A immunoglobulin Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Zhifei Biological Products Hepatitis A immunoglobulin Product Portfolio
  66. 8.11.5 Zhifei Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatitis A immunoglobulin Value Chain Analysis
  2. 9.1.1 Hepatitis A immunoglobulin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatitis A immunoglobulin Sales Mode & Process
  6. 9.2 Hepatitis A immunoglobulin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatitis A immunoglobulin Distributors
  9. 9.2.3 Hepatitis A immunoglobulin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst